Submitted:
29 March 2023
Posted:
30 March 2023
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and Methods
3. Chronic Systemic Inflammation
3.1. Evolution and the advantages of a proinflammatory design
3.2. Overview of the inflammatory response
3.2.1. Oxidative stress in PCOS
3.2.2. Advanced glycation end products and PCOS
3.2.3. Pattern recognition receptors and the innate immune system
3.2.4. Inflammasomes in PCOS
3.2.5. Adaptive immune response in PCOS
3.3. Neuroimmunomodulation and the link between the nervous system and PCOS
3.3.1. Anatomy of neuroendocrine-immune connections
3.3.2. Neuroimmunomodulation in PCOS
3.4. Hyperandrogenism and chronic inflammation
3.5. Summary of the role of inflammation in PCOS from an evolutionary perspective
4. Insulin Resistance and reduced insulin sensitivity
4.1. Physiological actions of insulin
| Functions of Insulin | Mechanism |
|---|---|
| Energy storage |
lipolysisglycogen synthesis gluconeogenesis |
| Anti-inflammatory |
AGE) Inhibits NF-κB activated cytokine production Inflammasome formation reduced Leukocyte adhesion to endothelium reduced |
| Volume expansion | sodium reabsorption |
| Vasodilation | endothelial nitric oxide |
| Tissue perfusion | Volume expansion and vasodilation |
| Evolutionary role of insulin | Tissue-specific energy storage and anabolic growth effects. Anti-inflammatory protective effect against excessive immune activation |
| Evolutionary role of insulin resistance | Maintain blood glucose to supply brain, immune cells, and fetus, during starvation, infection, stress and trauma. Proinflammatory |
4.2. Reduced insulin sensitivity versus insulin resistance in PCOS
4.3. Mechanisms of insulin resistance in PCOS
4.4. Evolutionary adaptive role of insulin resistance in PCOS
4.4.1. Insulin resistance and infection
4.4.2. Insulin resistance, starvation and dehydration
4.4.3. Insulin resistance and pregnancy
4.5. Insulin resistance and hyperandrogenism
5. Evolutionary significance of adipose tissue in PCOS
6. Central role of the microbiome in the pathogenesis of PCOS
7. Environmental and endocrine disrupting chemicals in PCOS
8. Evolutionary Model of PCOS and the Hallmarks of Health
| Hallmark | Polycystic Ovary Syndrome |
|---|---|
| Barrier integrity | Gastrointestinal permeability Respiratory mucosa |
| Containment of local perturbations | Mucosal and adaptive immunity ROS, AGE, DAMPS, PAMPS |
| Recycling and turnover | Autophagy, apoptosis, pyroptosis GI stem cell turnover |
| Integration of circuitries | Metabolic, reproductive neurological, circadian |
| Rhythmic oscillations | Menstrual cycle, circadian GI peristalsis |
| Homeostatic resilience | Endocrine, ANS metabolic, immune, microbiome |
| Hormetic regulation | oxidative stress, inactivity xenohormesis# |
| Repair and regeneration | Endoplasmic reticular stress mitochondrial stress |
9. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| ACTH | Adrenocorticotropic Hormone |
| AGE | Advanced Glycation End-Products |
| ANS | Autonomic Nervous System |
| AT | Adipose Tissue |
| BAT | Brown Adipose Tissue |
| CDR | Cell Danger Response |
| DAMPS | Danger Associated Molecular Patterns |
| DNA | Deoxyribose Nucleic Acid |
| EDC | Endocrine Disrupting Chemical |
| GDM | Gestational Diabetes |
| GI | Gastrointestinal |
| GLUT | Glucose Transporter |
| HPA | Hypothalamic-Pituitary-Adrenal |
| IR | Insulin Resistance |
| LH | Luteinizing Hormone |
| LPS | Lipopolysaccharide |
| PAMPS | Pathogen Associated Molecular Patterns |
| PCOS | Polycystic Ovary Syndrome |
| PNS | Peripheral Nervous System |
| PRR | Pattern Recognition Receptors |
| RAGE | Receptor of Advanced Glycation End-Products |
| RNA | Ribose Nucleic Acid |
| RNS | Reactive Nitrogen Species |
| ROS | Reactive Oxygen Species |
| SAT | Subcutaneous Adipose Tissue |
| SNS | Sympathetic Nervous System |
| TLR | Toll-like Receptor |
| TNF | Tumour Necrosis Factor |
| T2DM | Type 2 Diabetes Mellitis |
| WAT | White Adipose Tissue |
| VAT | Visceral Adipose Tissue |
References
- Parker J, O’brien C, Hawrelak J, Gersh FL. Polycystic Ovary Syndrome: An Evolutionary Adaptation to Lifestyle and the Environment. Int J Environ Res Public Health. 2022;19(3). [CrossRef]
- Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–79. [CrossRef]
- Cowan S, Lim S, Alycia C, Pirotta S, Thomson R, Gibson-Helm M, et al. Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity. BMC Endocr Disord [Internet]. 2023;23(1):14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36647089%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC9841505. [CrossRef]
- Pei Z, Lu W, Feng Y, Xu C, Hsueh AJW. Out of step societal and Darwinian adaptation during evolution is the cause of multiple women’s health issues. Hum Reprod. 2022;37(9):1959–69. [CrossRef]
- Dumesic DA, Padmanabhan V, Chazenbalk GD, Abbott DH. Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation. Reprod Biol Endocrinol [Internet]. 2022;20(1):1–12. Available from: https://doi.org/10.1186/s12958-021-00878-y. [CrossRef]
- Pathak G, Nichter M. Polycystic ovary syndrome in globalizing India: An ecosocial perspective on an emerging lifestyle disease. Soc Sci Med [Internet]. 2015;146(March 2017):21–8. Available from: http://dx.doi.org/10.1016/j.socscimed.2015.10.007. [CrossRef]
- Parker J, O’Brien C. Evolutionary and genetic antecedents to the pathogenesis of polycystic ovary syndrome (PCOS). J ACNEM. 2021;40(1).
- Aboeldalyl S, James C, Seyam E, Ibrahim EM, Shawki HED, Amer S. The role of chronic inflammation in polycystic ovarian syndrome—a systematic review and meta-analysis. Int J Mol Sci. 2021;22(5):1–31. [CrossRef]
- Giampaolino P, Foreste V, Di Filippo C, Gallo A, Mercorio A, Serafino P, et al. Microbiome and PCOS: State-of-art and future aspects. Int J Mol Sci. 2021;22(4):1–16. [CrossRef]
- Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci. 2019;236(October). [CrossRef]
- Palomba S, De Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575–92. [CrossRef]
- Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine [Internet]. 2018;62(2):318–25. Available from: http://dx.doi.org/10.1007/s12020-018-1692-3. [CrossRef]
- Zore T, Joshi N V., Lizneva D, Azziz R. Polycystic Ovarian Syndrome: Long-Term Health Consequences. Vol. 35, Seminars in Reproductive Medicine. 2017. p. 271–81. [CrossRef]
- Wu J, Yao XY, Shi RX, Liu SF, Wang XY. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: An update meta-analysis. Reprod Health. 2018;15(1):1–9. [CrossRef]
- Yumiceba, V., Lopez-Cortes, A., Perez-Villa A. Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome : An Integrative Analysis. Front Endocrinol (Lausanne). 2020;11(October):1–21. [CrossRef]
- Du Y, Li F, Li S, Ding L, Liu M. Causal relationship between polycystic ovary syndrome and chronic kidney disease : A Mendelian randomization study. Front Endocrinol 15 March 2023;(14):1–7. [CrossRef]
- Rodgers RJ, Avery JC, Moore VM, Davies MJ, Azziz R, Stener-Victorin E, et al. Complex diseases and co-morbidities: Polycystic ovary syndrome and type 2 diabetes mellitus. Endocr Connect. 2019;8(3):R71–5. [CrossRef]
- Parker J. NEM : A New Paradigm for Understanding the Common Origins of the Chronic Disease Epidemic. J ACNEM. 2018;37(3):6–11.
- Dunaif A. Perspectives in polycystic ovary syndrome: From hair to eternity. J Clin Endocrinol Metab. 2016;101(3):759–68. [CrossRef]
- Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018.
- Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100–4. [CrossRef]
- Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75(1):53–8. [CrossRef]
- Sun Q, Gao Y, Yang J, Lu J, Feng W, Yang W. Mendelian Randomization Analysis Identified Potential Genes Pleiotropically Associated with Polycystic Ovary Syndrome. Reprod Sci [Internet]. 2021; Available from: https://doi.org/10.1007/s43032-021-00776-z. [CrossRef]
- Zhu, Tiantian. Goodarzi M. Causes and consequences of polycystic ovary syndrome: Insights from Mendelian Randomization. J Clin Endocrinol Metab. epub ahead. [CrossRef]
- Lyle SM, Ahmed S, Elliott JE, Stener-Victorin E, Nachtigal MW, Drögemöller BI. Transcriptome-wide association analyses identify an association between ARL14EP and polycystic ovary syndrome. J Hum Genet. 2023;(August 2022). [CrossRef]
- Charifson MA, Trumble BC. Evolutionary origins of polycystic ovary syndrome: An environmental mismatch disorder. Evol Med Public Heal. 2019;2019(1):50–63. [CrossRef]
- Shaw LMA, Elton S. Polycystic ovary syndrome: A transgenerational evolutionary adaptation. BJOG An Int J Obstet Gynaecol. 2008;115(2):144–8.
- Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: Searching for the way out of the labyrinth. Hum Reprod Update. 2005;11(6):631–43. [CrossRef]
- Futuyma DJ. Evolutionary constraint and ecological consequences. Evolution (N Y). 2010;64(7):1865–84. [CrossRef]
- Ricklefs R, Wikelski M. The physiology/lifehistory nexus. Trends Ecol Evol [Internet]. 2002;17(10):462–8. Available from: https://ac.els-cdn.com/S0169534702025788/1-s2.0-S0169534702025788-main.pdf?_tid=9d9d8202-a223-11e7-9008-00000aacb35e&acdnat=1506366131_56ecc99336113d5fe5d529b4572abb84.
- Benton ML. The influence of evolutionary history on human health and disease. Nat Rev Genet [Internet]. 2021; Available from: http://dx.doi.org/10.1038/s41576-020-00305-9. [CrossRef]
- Brady SP, Bolnick DI, Barrett RDH, Chapman L, Crispo E, Derry AM, et al. Understanding maladaptation by uniting ecological and evolutionary perspectives. Am Nat. 2019;194(4):495–515. [CrossRef]
- Gluckman PD, Hanson MA, Spencer HG. Predictive adaptive responses and human evolution. Trends Ecol Evol. 2005;20(10):527–33. [CrossRef]
- Fay JC. Disease consequences of human adaptation. Appl Transl Genomics [Internet]. 2013;2(1):42–7. Available from: http://dx.doi.org/10.1016/j.atg.2013.08.001. [CrossRef]
- Casarini L, Simoni M, Brigante G. Is polycystic ovary syndrome a sexual conflict? A review. Reprod Biomed Online [Internet]. 2016;32(4):350–61. Available from: http://dx.doi.org/10.1016/j.rbmo.2016.01.011. [CrossRef]
- Itoh H, Ueda M, Suzuki M, Kohmura-Kobayashi Y. Developmental Origins of Metaflammation; A Bridge to the Future Between the DOHaD Theory and Evolutionary Biology. Front Endocrinol (Lausanne). 2022;13(February):1–7. [CrossRef]
- Chiang J. Liver Physiology: MetaboLism and Detoxification [Internet]. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. Elsevier Inc.; 2014. 1770–1782 p. Available from: http://dx.doi.org/10.1016/B978-0-12-386456-7.04202-7. [CrossRef]
- Roh E, Song DK, Kim MS. Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism. Exp Mol Med [Internet]. 2016;48(3):e216-12. Available from: http://dx.doi.org/10.1038/emm.2016.4. [CrossRef]
- Norman, R. Teede H. A new evidence-based guideline for assessment and management of polycystic ovary syndrome. Med J Aust. 2018;209(7):299–300. [CrossRef]
- Chodasewicz K. Evolution, reproduction and definition of life. Theory Biosci. 2014;133(1):39–45. [CrossRef]
- Corbett S, Morin-Papunen L. The Polycystic Ovary Syndrome and recent human evolution. Mol Cell Endocrinol [Internet]. 2013;373(1–2):39–50. Available from: http://dx.doi.org/10.1016/j.mce.2013.01.001. [CrossRef]
- Parker J. Glucose metabolism , energy production and regulation of cellular and whole-body metabolism. J ACNEM. 2020;39(1):29–33.
- Chantranupong L, Wolfson RL, Sabatini DM. Nutrient-sensing mechanisms across evolution. Cell [Internet]. 2015;161(1):67–83. Available from: http://dx.doi.org/10.1016/j.cell.2015.02.041. [CrossRef]
- Holly JMP, Biernacka K, Perks CM. Systemic metabolism, its regulators, and cancer: Past mistakes and future potential. Front Endocrinol (Lausanne). 2019;10(FEB):1–17. [CrossRef]
- Eiras MC, Pinheiro DP, Romcy KAM, Ferriani RA, Reis RM Dos, Furtado CLM. Polycystic Ovary Syndrome: the Epigenetics Behind the Disease. Reprod Sci. 2022;29(3):680–94. [CrossRef]
- Dapas M, Dunaif A. Deconstructing a Syndrome: Genomic Insights Into PCOS Causal Mechanisms and Classification. Endocr Rev. 2022;(February):927–65. [CrossRef]
- Smirnov, V. Beeraka, N. Yu Butko, D. Nikolenko, V. Bondarev, S. Achkasov, E. Sinelnikov, M. Vikram P. Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS. Reprod Sci. 2022.
- Parker J. Emerging Concepts in the Pathogenesis and Treatment of Polycystic Ovary Syndrome. Curr Womens Health Rev. 2016;10(2):107–12. [CrossRef]
- Azziz R, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: An ancient disorder? Fertil Steril [Internet]. 2011;95(5):1544–8. Available from: http://dx.doi.org/10.1016/j.fertnstert.2010.09.032. [CrossRef]
- Gluckman PD, Low FM, Hanson MA. Anthropocene-related disease. Evol Med Public Heal. 2020;2020(1):304–10. [CrossRef]
- Lee HJ, Hore TA, Reik W. Reprogramming the methylome: Erasing memory and creating diversity. Cell Stem Cell [Internet]. 2014;14(6):710–9. Available from: http://dx.doi.org/10.1016/j.stem.2014.05.008. [CrossRef]
- Monk D, Mackay DJG, Eggermann T, Maher ER, Riccio A. Genomic imprinting disorders: lessons on how genome, epigenome and environment interact. Nat Rev Genet [Internet]. 2019;20(4):235–48. Available from: http://dx.doi.org/10.1038/s41576-018-0092-0. [CrossRef]
- Rubio-Ruiz ME, Peredo-Escárcega AE, Cano-Martínez A, Guarner-Lans V. An Evolutionary Perspective of Nutrition and Inflammation as Mechanisms of Cardiovascular Disease. Int J Evol Biol. 2015;2015:1–10. [CrossRef]
- Watve MG, Yajnik CS. Evolutionary origins of insulin resistance: A behavioral switch hypothesis. BMC Evol Biol. 2007;7:1–13. [CrossRef]
- Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab. 2019;29(5):1028–44. [CrossRef]
- Szukiewicz D, Trojanowski S, Kociszewska A, Szewczyk G. Modulation of the Inflammatory Response in Polycystic Ovary Syndrome (PCOS)—Searching for Epigenetic Factors. Int J Mol Sci. 2022;23(23). [CrossRef]
- Shorakae S, Ranasinha S, Abell S, Lambert G, Lambert E, de Courten B, et al. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. Clinical Endocrinology. 2018;89:628–33. [CrossRef]
- Barlampa D, Bompoula MS, Bargiota A, Kalantaridou S, Mastorakos G, Valsamakis G. Hypothalamic inflammation as a potential pathophysiologic basis for the heterogeneity of clinical, hormonal, and metabolic presentation in pcos. Nutrients. 2021;13(2):1–17. [CrossRef]
- López-Otín C, Kroemer G. Hallmarks of Health. Cell. 2021;184(1):33–63.
- Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol [Internet]. 2012;22(17):R733–40. Available from: http://dx.doi.org/10.1016/j.cub.2012.07.029. [CrossRef]
- Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med [Internet]. 2019;25(12):1822–32. Available from: http://dx.doi.org/10.1038/s41591-019-0675-0. [CrossRef]
- Naviaux RK. Metabolic features and regulation of the healing cycle—A new model for chronic disease pathogenesis and treatment. Mitochondrion [Internet]. 2019;46(April 2018):278–97. Available from: https://doi.org/10.1016/j.mito.2018.08.001. [CrossRef]
- Yu SY, Li XL. Pyroptosis and inflammasomes in obstetrical and gynecological diseases. Gynecol Endocrinol [Internet]. 2021;37(5):385–91. Available from: https://doi.org/10.1080/09513590.2021.1871893. [CrossRef]
- Katayama PL, Leirão IP, Kanashiro A, Luiz JPM, Cunha FQ, Navegantes LCC, et al. The carotid body detects circulating tumor necrosis factor-alpha to activate a sympathetic anti-inflammatory reflex. Brain Behav Immun. 2022;102(December 2021):370–86. [CrossRef]
- Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA) - A novel theory for the development of Polycystic Ovarian Syndrome. Med Hypotheses [Internet]. 2012;79(1):104–12. Available from: http://dx.doi.org/10.1016/j.mehy.2012.04.016. [CrossRef]
- Xiong P, Zhang F, Liu F, Zhao J, Huang X. Metaflammation in glucolipid metabolic disorders : Pathogenesis and treatment. Biomed Pharmacother [Internet]. 2023;161(March):114545. Available from: https://doi.org/10.1016/j.biopha.2023.114545. [CrossRef]
- Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, et al. A guiding map for inflammation. Nat Immunol [Internet]. 2017;18(8):826–31. Available from: http://dx.doi.org/10.1038/ni.3790. [CrossRef]
- Zhang H, Zhu J, Gong Z, Zhu JK. Abiotic stress responses in plants. Nat Rev Genet. 2022;23(2):104–19.
- Khan RN, Hay DP. A clear and present danger: Inflammasomes DAMPing down disorders of pregnancy. Hum Reprod Update. 2015;21(3):388–405.
- Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9(OCT):1–19. [CrossRef]
- Cavalier-Smith T. Cell evolution and Earth history: Stasis and revolution. Philos Trans R Soc B Biol Sci. 2006;361(1470):969–1006. [CrossRef]
- Tang KH, Blankenship RE. Both forward and reverse TCA cycles operate in green sulfur bacteria. J Biol Chem [Internet]. 2010;285(46):35848–54. Available from: http://dx.doi.org/10.1074/jbc.M110.157834. [CrossRef]
- Medeiros HCD, Lunt SY. The Warburg effect: Saturation of mitochondrial NADH shuttles triggers aerobic lactate fermentation. Mol Cell [Internet]. 2022;82(17):3119–21. Available from: https://doi.org/10.1016/j.molcel.2022.08.004. [CrossRef]
- Naviaux RK. Oxidative shielding or oxidative stress? J Pharmacol Exp Ther. 2012;342(3):608–18.
- Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541. [CrossRef]
- Dabravolski SA, Nikiforov NG, Eid AH, Nedosugova L V., Starodubova A V., Popkova T V., et al. Mitochondrial dysfunction and chronic inflammation in polycystic ovary syndrome. Int J Mol Sci. 2021;22(8):1–20. [CrossRef]
- Zhao H, Zhao Y, Li T, Li M, Li J, Li R, et al. Metabolism alteration in follicular niche: The nexus among intermediary metabolism, mitochondrial function, and classic polycystic ovary syndrome. Free Radic Biol Med [Internet]. 2015;86(49):295–307. Available from: http://dx.doi.org/10.1016/j.freeradbiomed.2015.05.013. [CrossRef]
- Mohammadi M. Oxidative Stress and Polycystic Ovary Syndrome: A Brief Review. Int J Prev Med. 2017;8:1–7. [CrossRef]
- Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev. 2016;2016. [CrossRef]
- Sharifi-Rad M, Anil Kumar N V., Zucca P, Varoni EM, Dini L, Panzarini E, et al. Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases. Front Physiol. 2020;11(July):1–21. [CrossRef]
- Herman R, Jensterle M, Janež A, Goričar K, Dolžan V. Genetic variability in antioxidative and inflammatory pathways modifies the risk for PCOs and influences metabolic profile of the syndrome. Metabolites. 2020;10(11):1–18. [CrossRef]
- Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030. [CrossRef]
- Rashidi B, Haghollahi F, Shariat M, Zayerii F. The Effects of Calcium-Vitamin D and Metformin on Polycystic Ovary Syndrome: A Pilot Study. Taiwan J Obstet Gynecol [Internet]. 2009;48(2):142–7. Available from: http://dx.doi.org/10.1016/S1028-4559(09)60275-8. [CrossRef]
- Kaya C, Erkan AF, Cengiz SD, Dünder I, Demirel ÖE, Bilgihan A. Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome. Fertil Steril. 2009;92(4):1372–7. [CrossRef]
- Enechukwu CI, Onuegbu AJ, Olisekodiaka MJ, Eleje GU, Ikechebelu JI, Ugboaja JO, et al. Oxidative stress markers and lipid profiles of patients with polycystic ovary syndrome in a Nigerian tertiary hospital. Obstet Gynecol Sci. 2019;62(5):335–43. [CrossRef]
- Dincer Y, Akcay T, Erdem T, Ilker Saygili E, Gundogdu S. DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome. Scand J Clin Lab Invest. 2005;65(8):721–8. [CrossRef]
- Noormohammadi M, Eslamian G, Malek S, Shoaibinobarian N, Mirmohammadali SN. The association between fertility diet score and polycystic ovary syndrome: A Case-Control study. Health Care Women Int [Internet]. 2022;43(1–3):70–84. Available from: https://doi.org/10.1080/07399332.2021.1886298. [CrossRef]
- Shoaibinobarian N, Eslamian G, Noormohammadi M, Malek S, Rouhani S, Mirmohammadali SN. Dietary Total Antioxidant Capacity and Risk of Polycystic Ovary Syndrome: A Case-Control Study. Int J Fertil Steril. 2022;16(3):200–5. [CrossRef]
- Parker, J. Hawrelak, J. Gersh F. Nutritional Role of Polyphenols As a Component of a Wholefood Diet in the Management of Polycystic Ovary Syndrome. J ACNEM [Internet]. 2021;40(2):6–12. Available from: https://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=154032844&lang=ja&site=ehost-live.
- Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: Emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab. 2012;97(7):2231–42. [CrossRef]
- Inagi R. Inhibitors of advanced glycation and endoplasmic reticulum stress [Internet]. 1st ed. Vol. 491, Methods in Enzymology. Elsevier Inc.; 2011. 361–380 p. Available from: http://dx.doi.org/10.1016/B978-0-12-385928-0.00020-1. [CrossRef]
- Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104(8):1287–91. [CrossRef]
- Garg D, Merhi Z. Advanced glycation end products: Link between diet and ovulatory dysfunction in PCOS? Nutrients. 2015;7(12):10129–44.
- Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis. 2008;196(1):9–21. [CrossRef]
- Kathryn C. B. Tan; Sammy W. M. Shiu; Ying Wong; Xystus Tam. Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev. 2011;27:1488–92. [CrossRef]
- Palimeri S, Palioura E, Diamanti-Kandarakis E. Current perspectives on the health risks associated with the consumption of advanced glycation end products: Recommendations for dietary management. Diabetes, Metab Syndr Obes Targets Ther. 2015;8:415–26. [CrossRef]
- Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol. 2007;127(6):581–9. [CrossRef]
- Azhary JMK, Harada M, Kunitomi C, Kusamoto A, Takahashi N, Nose E, et al. Androgens Increase Accumulation of Advanced Glycation End Products in Granulosa Cells by Activating ER Stress in PCOS. Endocrinol (United States). 2020;161(2):1–13.
- Tatone C, Di Emidio G, Placidi M, Rossi G, Ruggieri S, Taccaliti C, et al. AGEs-related dysfunctions in PCOS: Evidence from animal and clinical research. J Endocrinol. 2021;251(2):R1–9. [CrossRef]
- Garg D, Merhi Z. Relationship between Advanced Glycation End Products and Steroidogenesis in PCOS. Reprod Biol Endocrinol [Internet]. 2016;14(1):1–13. Available from: http://dx.doi.org/10.1186/s12958-016-0205-6. [CrossRef]
- Van Der Lugt T, Weseler AR, Gebbink WA, Vrolijk MF, Opperhuizen A, Bast A. Dietary advanced glycation endproducts induce an inflammatory response in human macrophages in vitro. Nutrients. 2018;10(12):1–10. [CrossRef]
- Uribarri J, del Castillo MD, de la Maza MP, Filip R, Gugliucci A, Luevano-Contreras C, et al. Dietary advanced glycation end products and their role in health and disease. Adv Nutr. 2015;6(4):461–73. [CrossRef]
- Tantalaki E, Piperi C, Livadas S, Kollias A, Adamopoulos C, Koulouri A, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones. 2014;13(1):65–73. [CrossRef]
- Vlassara H, Striker GE. AGE restriction in diabetes mellitus: A paradigm shift. Nat Rev Endocrinol. 2011;7(9):526–39. [CrossRef]
- Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54(1):1–13.
- Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.
- Naviaux RK. Metabolic features of the cell danger response. Mitochondrion [Internet]. 2014;16:7–17. Available from: http://dx.doi.org/10.1016/j.mito.2013.08.006. [CrossRef]
- Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374–95.
- Costa-Mattioli M, Walter P. The integrated stress response: From mechanism to disease. Science. 2020;368(6489). [CrossRef]
- Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther [Internet]. 2021;6(1):1–24. Available from: http://dx.doi.org/10.1038/s41392-021-00687-0. [CrossRef]
- Moretti J, Blander JM. Insights into phagocytosis-coupled activation of pattern recognition receptors and inflammasomes. Curr Opin Immunol [Internet]. 2014;26(1):100–10. Available from: http://dx.doi.org/10.1016/j.coi.2013.11.003. [CrossRef]
- Zhou F, Li C, Zhang SY. NLRP3 inflammasome: a new therapeutic target for high-risk reproductive disorders? Chin Med J (Engl). 2020;134(1):20–7.
- Moretti J, Blander JM. Cell-autonomous stress responses in innate immunity. J Leukoc Biol. 2017;101(1):77–86. [CrossRef]
- Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72. [CrossRef]
- Parker J, O’Brien C, Hawrelak J. A narrative review of the role of gastrointestinal dysbiosis in the pathogenesis of polycystic ovary syndrome. Obstet Gynecol Sci. 2022;65(1):14-28. [CrossRef]
- Murthi P, Pinar AA, Dimitriadis E, Samuel CS. Inflammasomes—a molecular link for altered immunoregulation and inflammation mediated vascular dysfunction in preeclampsia. Int J Mol Sci. 2020;21(4). [CrossRef]
- Rostamtabar, M. Esmaeilzadeh, M. Tourani, M. Rahmani, A. Baee, M. Shirafkan, F. Saleki, K. Mirzababayi, S. Ebrahimpour, S. Nouri H. Pathophysiological roles of chronic low-grade inflammation in polycystic ovary syndrome. J Cell Physiol. 2020;236:824–38.
- Eltzschig, HK. Sitkovsky, MV. Robson S. Purinergic Signaling during Inflammation. N Engl J Med. 2013;368(13):1260–1260.
- Rostamtabar M, Esmaeilzadeh S, Karkhah A, Amiri M, Rahmani A, Bakouei F, et al. Elevated expression of IL-18 but not IL-1β gene is associated with NALP3 and AIM2 inflammasome in Polycystic Ovary Syndrome. Gene [Internet]. 2020;731(January):144352. Available from: https://doi.org/10.1016/j.gene.2020.144352. [CrossRef]
- Guo QJ, Shan J, Xu YF, Hu YY, Huo CL, Song JY, et al. Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. Mediators Inflamm. 2020;2020. [CrossRef]
- Hu C, Pang B, Ma Z, Yi H. Immunophenotypic profiles in polycystic ovary syndrome. Mediators Inflamm. 2020;2020. [CrossRef]
- Mahajan S, Vita R, Shackelford D, Lane J, Schulten V, Zarebski L, et al. Epitope specific antibodies and T cell receptors in the immune epitope database. Front Immunol. 2018;9(NOV):1–10. [CrossRef]
- Rees AR. Understanding the human antibody repertoire. MAbs [Internet]. 2020;12(1):1–16. Available from: https://doi.org/10.1080/19420862.2020.1729683. [CrossRef]
- Alberto Kölliker Frers R, Otero-Losada M, Inés Herrera M, Porta S, Cosentino V, Kerzberg E, et al. Immune-Mediated Inflammation: Human T CD4 Helper Lymphocyte Diversity and Plasticity in Health and Disease. In: Ota Fuchs and Seyyed Shamsadin Athari, editor. Cells of the Immune System [Internet]. 1st ed. Intehopen; 2020. p. 1–14. Available from: https://www.intechopen.com/chapters/69166.
- Sbierski-Kind J, Goldeck D, Buchmann N, Spranger J, Volk HD, Steinhagen-Thiessen E, et al. T cell phenotypes associated with insulin resistance: results from the Berlin Aging Study II. Immun Ageing. 2020;17(1):1–11. [CrossRef]
- Wu R, Fujii S, Ryan NK, Van der Hoek KH, Jasper MJ, Sini I, et al. Ovarian leukocyte distribution and cytokine/chemokine mRNA expression in follicular fluid cells in women with polycystic ovary syndrome. Hum Reprod. 2007;22(2):527–35. [CrossRef]
- Krishna MB, Joseph A, Subramaniam AG, Gupta A, Pillai SM, Laloraya M. Reduced tregs in peripheral blood of PCOS patients - A consequence of aberrant Il2 signaling. J Clin Endocrinol Metab. 2015;100(1):282–92. [CrossRef]
- Ma M, Wang M, Xu F, Hao S. The Imbalance in Th17 and Treg Cells in Polycystic Ovarian Syndrome Patients with Autoimmune Thyroiditis. Immunol Invest [Internet]. 2022;51(5):1170–81. Available from: https://doi.org/10.1080/08820139.2021.1915329. [CrossRef]
- Luan Y yi, Zhang L, Peng Y qiu, Li Y ying, Liu R xia, Yin C hong. Immune regulation in polycystic ovary syndrome. Clin Chim Acta [Internet]. 2022;531(January):265–72. Available from: https://doi.org/10.1016/j.cca.2022.04.234. [CrossRef]
- Salvador AF, de Lima KA, Kipnis J. Neuromodulation by the immune system: a focus on cytokines. Nat Rev Immunol [Internet]. 2021;21(8):526–41. Available from: http://dx.doi.org/10.1038/s41577-021-00508-z. [CrossRef]
- Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. Vol. 182, Journal of Steroid Biochemistry and Molecular Biology. 2018;182:27–36.
- Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The Cholinergic Anti-inflammatory Pathway: A Missing Link in Neuroimmunomodulation. Mol Med. 2003;9(5–8):125–34. [CrossRef]
- Bellocchi C, Carandina A, Montinaro B, Targetti E, Furlan L, Rodrigues GD, et al. The Interplay between Autonomic Nervous System and Inflammation across Systemic Autoimmune Diseases. Int J Mol Sci. 2022;23(5). [CrossRef]
- Ingegnoli F, Buoli M, Antonucci F, Coletto LA, Esposito CM, Caporali R. The Link Between Autonomic Nervous System and Rheumatoid Arthritis: From Bench to Bedside. Front Med. 2020;7(December):1–11. [CrossRef]
- del Rey A, Besedovsky HO, Sorkin E, da Prada M, Arrenbrecht S. Immunoregulation mediated by the sympathetic nervous system, II. Cell Immunol. 1981;63(2):329–34. [CrossRef]
- Martelli D. The inflammatory reflex reloaded. Brain Behav Immun [Internet]. 2022;104:137–8. Available from: https://doi.org/10.1016/j.bbi.2022.06.001. [CrossRef]
- Zangeneh FZ, Bagheri M, Naghizadeh MM. Hyponeurotrophinemia in Serum of Women with Polycystic Ovary Syndrome as a Low Grade Chronic Inflammation. Open J Obstet Gynecol. 2015;05(09):459–69. [CrossRef]
- Tracey KJ. The inflammatory reflex. Nature. 2002;420(December):853–8.
- WEXLER BC, DOLGIN AE, TRYCZYNSKI EW. Effects of a bacterial polysaccharide (piromen) on the pituitary-adrenal axis: adrenal ascorbic acid, cholesterol and histologic alterations. Endocrinology. 1957;61(3):300–8.
- Banks, WA. Kastin, AJ. Broadwell R. یلیPassage of cytokines across the blood-brain-barrier. Neuroimmunomodulation. 1995;2(24):1–8.
- Buller KM. Role of circumventricular organs in pro-inflammatory cytokine-induced activation of the hypothalamic-pituitary-adrenal axis. Clin Exp Pharmacol Physiol. 2001;28(7):581–9.
- Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci Basic Clin. 2000;85(1–3):1–17. [CrossRef]
- Dag ZO, Alpua M, Turkel Y, Isik Y. Autonomic dysfunction in patients with polycystic ovary syndrome. Taiwan J Obstet Gynecol [Internet]. 2015;54(4):381–4. Available from: http://dx.doi.org/10.1016/j.tjog.2015.03.002. [CrossRef]
- Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol. 2002;20:125–63. [CrossRef]
- Shaikh S, Verma H, Yadav N, Jauhari M, Bullangowda J. Applications of Steroid in Clinical Practice: A Review. ISRN Anesthesiol. 2012;2012:1–11. [CrossRef]
- McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: Interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr Rev. 1999;20(4):435–59.
- Kox M, Van Eijk LT, Zwaag J, Van Den Wildenberg J, Sweep FCGJ, Van Der Hoeven JG, et al. Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans. Proc Natl Acad Sci U S A. 2014;111(20):7379–84. [CrossRef]
- Sun P, Liu DG, Ye XM. Nicotinic Acetylcholine Receptor α7 Subunit Is an Essential Regulator of Seizure Susceptibility. Front Neurol. 2021;12(January):1–5. [CrossRef]
- Lansdown A, Rees DA. The sympathetic nervous system in polycystic ovary syndrome: A novel therapeutic target? Clin Endocrinol (Oxf). 2012;77(6):791–801.
- Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS. Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension. 2007;49(6):1442–7. [CrossRef]
- Perciaccante A, Fiorentini A, Valente R, Tubani L. Polycystic ovary syndrome: Androgens, autonomic nervous system, and hypertension [7]. Hypertension. 2007;50(1):91710. [CrossRef]
- Dissen GA, Parrott JA, Skinner MK, Hill DF, Costa ME, Ojeda SR. Direct effects of nerve growth factor on thecal cells from antral ovarian follicles. Endocrinology. 2000;141(12):4736–50. [CrossRef]
- Dissen GA, Garcia-Rudaz C, Paredes A, Mayer C, Mayerhofer A, Ojeda SR. Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinology. 2009;150(6):2906–14. [CrossRef]
- Giallauria F, Palomba S, Maresca L, Vuolo L, Tafuri D, Lombardi G, et al. Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2008;69(5):792–8. [CrossRef]
- 155. Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol, Available from. [CrossRef]
- González, F. Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids.
- 157. Wagner IV, Savchuk I, Sahlin L, Kulle A, Klöting N, Dietrich A, et al. De Novo and Depot-Specific Androgen Production in Human Adipose Tissue: A Source of Hyperandrogenism in Women with Obesity. Obes Facts.
- 158. Velez LM, Seldin M, Motta AB. Inflammation and reproductive function in women with polycystic ovary syndrome. Biol Reprod.
- 159. Xiong YL, Liang XY, Yang X, Li Y, Wei LN. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol.
- 160. Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Paterakis T, et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest.
- 161. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: A systematic review and metaanalysis. Fertil Steril.
- 162. Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev.
- 163. Azhary JMK, Harada M, Takahashi N, Nose E, Kunitomi C, Koike H, et al. Endoplasmic reticulum stress activated by androgen enhances apoptosis of granulosa cells via induction of death receptor 5 in PCOS. Endocrinology.
- 164. Koike H, Harada M, Kusamoto A, Xu Z, Tanaka T, Sakaguchi N, et al. Roles of endoplasmic reticulum stress in the pathophysiology of polycystic ovary syndrome. Front Endocrinol, 1124.
- 165. Li Y, Zheng Q, Sun D, Cui X, Chen S, Bulbul A, et al. Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome. J Cell Physiol.
- 166. Zhai Y, Pang Y. Systemic and ovarian inflammation in women with polycystic ovary syndrome. J Reprod Immunol, Available from, 1036. [CrossRef]
- 167. Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, et al. Role of insulin in health and disease: An update. Int J Mol Sci.
- Fu Z, R. Gilbert E, Liu D. Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes. Curr Diabetes Rev.
- 169. Watanabe M, Hayasaki H, Tamayama T, Shimada M. Histologic distribution of insulin and glucagon receptors. Brazilian J Med Biol Res.
- 170. Khalid M, Alkaabi J, Khan MAB, Adem A. Insulin signal transduction perturbations in insulin resistance. Int J Mol Sci.
- 171. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev.
- 172. Zhou MS, Wang A, Yu H. Link between insulin resistance and hypertension: What is the evidence from evolutionary biology? Diabetol Metab Syndr.
- 173. Sun Q, Li J, Gao F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J Diabetes.
- 174. Chang YW, Hung LC, Chen YC, Wang WH, Lin CY, Tzeng HH, et al. Insulin Reduces Inflammation by Regulating the Activation of the NLRP3 Inflammasome. Front Immunol.
- 175. Fernández-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia.
- Wan, YY. Regulatory T cells: Immune suppression and beyond. Cell Mol Immunol, 2010;7(3):204–10. Available from, 2010. [Google Scholar] [CrossRef]
- 177. Jacobse J, Li J, Rings EHHM, Samsom JN, Goettel JA. Intestinal Regulatory T Cells as Specialized Tissue-Restricted Immune Cells in Intestinal Immune Homeostasis and Disease. Front Immunol.
- Makhijani, P. Basso, PJ. Chan, YT. Chen, N. Baechle, J. Khan, S. Furman, D. Tsai, S. Winer D. Regulation of the immune system by the insulin receptor in health and disease. Front Endocrinol, 1: 2023;(March), 2023. [Google Scholar]
- 179. Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod.
- 180. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod.
- 181. Katic M, Kahn CR. The role of insulin and IGF-1 signaling in longevity. Cell Mol Life Sci.
- Cibula, D. Is insulin resistance an essential component of PCOS? The influence of confounding factors. Hum Reprod.
- 183. Plomin R, Haworth CMA, Davis OSP. Common disorders are quantitative traits. Nat Rev Genet, Available from. [CrossRef]
- 184. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care.
- 185. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes.
- 186. Teede HJ, Hutchison SK, Zoungas S. The management of insulin resistance in polycystic ovary syndrome. Trends Endocrinol Metab.
- 187. Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord.
- 188. Morciano A, Romani F, Sagnella F, Scarinci E, Palla C, Moro F, et al. Assessment of insulin resistance in lean women with polycystic ovary syndrome. Fertil Steril, Available from. [CrossRef]
- 189. Gorjão R, Takahashi HK, Pan JA, Massao Hirabara S. Molecular mechanisms involved in inflammation and insulin resistance in chronic diseases and possible interventions. J Biomed Biotechnol.
- 190. Fernandez M, Murillo A. Dietary Treatments to Reduce Insulin Resistance and Inflammation in Type-2 Diabetic Patients. Med Res Arch.
- Tsatsoulis, A. Mantzaris, MD. Sofia, B. Andrikoula M. Insulin resistance: An adaptive mechanism becomes maladaptive in the current environment - An evolutionary perspective. Metabolism.
- 192. Wensveen FM, Šestan M, Turk Wensveen T, Polić B. ‘Beauty and the beast’ in infection: How immune–endocrine interactions regulate systemic metabolism in the context of infection. Eur J Immunol.
- 193. Wang P, Mariman ECM. Insulin resistance in an energy-centered perspective. Physiol Behav.
- 194. Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview. J Diabetes Res.
- 195. Sprague JE, Gandica R, Kelsey MM. Insulin Resistance in Puberty. Contemporary Endocrinology.
- 196. Straub RH, Cutolo M, Buttgereit F, Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med.
- 197. Rabasa C, Dickson SL. Impact of stress on metabolism and energy balance. Curr Opin Behav Sci, Available from. [CrossRef]
- 198. Ieronymaki E, Daskalaki MG, Lyroni K, Tsatsanis C. Insulin signaling and insulin resistance facilitate trained immunity in macrophages through metabolic and epigenetic changes. Front Immunol.
- 199. Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018. National Health and Medical Research Council.
- Chaudhari, AP. Mazumdar K, Deepak P. Anxiety, Depression, and Quality of Life in Women with Polycystic Ovarian Syndrome. Indian J Psychol Med.
- 201. Soeters MR, Soeters PB. The evolutionary benefit of insulin resistance. Clin Nutr.
- 202. Soeters MR, Sauerwein HP, Dubbelhuis PF, Groener JE, Ackermans MT, Fliers E, et al. Muscle adaptation to short-term fasting in healthy lean humans. J Clin Endocrinol Metab.
- 203. Horita S, Seki G, Yamada H, Suzuki M, Koike K, Fujita T. Insulin resistance, obesity, hypertension, and renal sodium transport. Int J Hypertens.
- 204. Velloso LA, Folli F, Perego L, Saad MJA. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes/Metabolism Research and Reviews.
- 205. Zhou MS, Schulman IH, Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: Role of nuclear factor kappa B activation. J Hypertens.
- 206. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab.
- Sonagra, AD. Normal Pregnancy- A State of Insulin Resistance. J Clin Diagnostic Res.
- 208. Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol.
- 209. Jayabalan N, Nair S, Nuzhat Z, Rice GE, Zuñiga FA, Sobrevia L, et al. Cross talk between adipose tissue and placenta in obese and gestational diabetes mellitus pregnancies via exosomes. Front Endocrinol.
- 210. Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Kling Bäckhed H, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell.
- 211. Li X, Liu X, Zuo Y, Gao J, Liu Y, Zheng W. The risk factors of gestational diabetes mellitus in patients with polycystic ovary syndrome: What should we care. Med, 2652.
- 212. Yan Q, Qiu D, Liu X, Xing Q, Liu R, Hu Y. The incidence of gestational diabetes mellitus among women with polycystic ovary syndrome: a meta-analysis of longitudinal studies. BMC Pregnancy Childbirth, Available from. [CrossRef]
- Noctor, E. Type 2 diabetes after gestational diabetes: The influence of changing diagnostic criteria. World J Diabetes.
- 214. Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 2 diabetes in women with a known history of gestational diabetes: Systematic review and meta-analysis. BMJ.
- 215. Bonora E, Trombetta M, Dauriz M, Travia D, Cacciatori V, Brangani C, et al. Chronic complications in patients with newly diagnosed type 2 diabetes: Prevalence and related metabolic and clinical features: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 9. BMJ Open Diabetes Res Care.
- Bolton, A. International Diabetes Federation Diabetes Atlas [Internet]. 10th ed. Bolton A, editor. Vol. 102, Diabetes Research and Clinical Practice. 2021. Available from: www.diabetesatlas.
- 217. Yang J, Qian F, Chavarro JE, Ley SH, Tobias DK, Yeung E, et al. Modifiable risk factors and long term risk of type 2 diabetes among individuals with a history of gestational diabetes mellitus: prospective cohort study. BMJ.
- Patel, S. Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review. J Steroid Biochem Mol Biol, 2017;168:19–25. Available from, 2017. [Google Scholar] [CrossRef]
- 219. Evans SF, Hull ML, Hutchinson MR, Rolan PE. Androgens, Endometriosis and Pain. Front Reprod Heal.
- 220. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab.
- POLDERMAN, KH. GOOREN, LJ. ASSCHEMAN H. Induction of Insulin Resistance by Androgens and Estrogens. J Clin Endocrinol Metab, /: 1994;79(79):265–71. Available from: https, 1994. [Google Scholar]
- 222. Skinner MK, Schmidt M, Savenkova MI, Sadler-Riggleman I, Nilsson EE. Regulation of granulosa and theca cell transcriptomes during ovarian antral follicle development. Mol Reprod Dev.
- Clegg, DJ. Minireview: The year in review of estrogen regulation of metabolism. Mol Endocrinol. 1957. [Google Scholar]
- Stocco, C. Aromatase expression in the ovary: Hormonal and molecular regulation. Steroids.
- 225. Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci.
- 226. Di Nardo G, Zhang C, Marcelli AG, Gilardi G. Molecular and structural evolution of cytochrome p450 aromatase. Int J Mol Sci.
- 227. Simeon S, Spjuth O, Lapins M, Nabu S, Anuwongcharoen N, Prachayasittikul V, et al. Origin of aromatase inhibitory activity via proteochemometric modeling. Peer J.
- 228. Conley A, Mapes S, Jo Corbin C, Greger D, Graham S. Structural determinants of aromatase cytochrome p450 inhibition in substrate recognition site-1. Mol Endocrinol.
- 229. Jin Y, Choi YJ, Heo K, Park SJ. Melatonin as an oncostatic molecule based on its anti-aromatase role in breast cancer. Int J Mol Sci.
- 230. Cheng JC, Fang L, Li Y, Wang S, Li Y, Yan Y, et al. Melatonin stimulates aromatase expression and estradiol production in human granulosa-lutein cells: relevance for high serum estradiol levels in patients with ovarian hyperstimulation syndrome. Exp Mol Med.
- Kim JY, Han EH, Kim HG, Oh KN, Kim SK, Lee KY, et al. Bisphenol A-induced aromatase activation is mediated by cyclooxygenase-2 up-regulation in rat testicular Leydig cells. Toxicol Lett [Internet]. 2010;193(2):200–8. Available from. [CrossRef]
- 232. Maia H, Haddad C, Pinheiro N, Casoy J. The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis. Int J Womens Health.
- 233. Wang C, Mäkelä T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol.
- 234. Singh S, Awasthi M, Pandey VP, Dwivedi UN. Plant derived anti-cancerous secondary metabolites as multipronged inhibitor of COX, Topo, and aromatase: molecular modeling and dynamics simulation analyses. J Biomol Struct Dyn, Available from, 3082. [CrossRef]
- 235. Richard S, Moslemi S, Sipahutar H, Benachour N, Seralini GE. Differential effects of glyphosate and roundup on human placental cells and aromatase. Environ Health Perspect.
- 236. Zarn JA, Brüschweiler BJ, Schlatter JR. Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14α-demethylase and aromatase. Environ Health Perspect.
- 237. Rojas J, Chávez-Castillo M, Torres W, Arraiz N, Cabrera M. Metformin in Cancer: Chemical Pathways for Tumoral Control Independent of Amp-Dependent Kinase. J Endocrinol Diabetes Obes.
- 238. Biegon A, Alia-Klein N, Fowler JS. Potential contribution of aromatase inhibition to the effects of nicotine and related compounds on the brain. Front Pharmacol.
- 239. Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J.
- Baillargeon JP, Nestler JE. Commentary: Polycystic ovary syndrome: A syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab. 2006;91(1):22–4.
- 241. Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res, Available from. [CrossRef]
- 242. Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril.
- Ibáñez L, Potau N, Zampolli M, Riqué S, Saenger P, Carrascosa A. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab. 1997;82(7):2283–8.
- 244. Soldani R, Cagnacci A, Yen SSC. Insulin insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur J Endocrinol.
- 245. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab.
- 246. Chan O, Inouye K, Akirav E, Park E, Riddell MC, Vranic M, et al. Insulin alone increases hypothalamo-pituitary-adrenal activity, and diabetes lowers peak stress responses. Endocrinology.
- 247. Kanbour SA, Dobs AS. Hyperandrogenism in Women with Polycystic Ovarian Syndrome: Pathophysiology and Controversies. Androgens.
- 248. Pateguana NB, Janes A. The contribution of hyperinsulinemia to the hyperandrogenism of polycystic ovary syndrome. J Insul Resist.
- 249. Vyrides AA, El Mahdi E, Giannakou K. Ovulation induction techniques in women with polycystic ovary syndrome. Front Med.
- 250. Panth N, Gavarkovs A, Tamez M, Mattei J. The Influence of Diet on Fertility and the Implications for Public Health Nutrition in the United States. Front Public Heal.
- Elnashar, AM. The role of metformin in ovulation induction: Current status. Middle East Fertil Soc J, 2011;16(3):175–81. Available from, 2011. [Google Scholar] [CrossRef]
- 252. Nehir Aytan A, Bastu E, Demiral I, Bulut H, Dogan M, Buyru F. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol.
- West-Eberhard, MJ. Nutrition, the visceral immune system, and the evolutionary origins of pathogenic obesity. Proc Natl Acad Sci U S A. 2019;116(3):723–31.
- 254. Ottaviani E, Malagoli D, Franceschi C. The evolution of the adipose tissue: A neglected enigma. Gen Comp Endocrinol, Available from. [CrossRef]
- Kuzawa, CW. Adipose Tissue in Human Infancy and Childhood: An Evolutionary Perspective. Yearb Phys Anthropol.
- 256. Parra-Peralbo E, Talamillo A, Barrio R. Origin and Development of the Adipose Tissue, a Key Organ in Physiology and Disease. Front Cell Dev Biol.
- Ibrahim, MM. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes Rev. 2010;11(1):11–8.
- 258. Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction.
- 259. Scheja L, Heeren J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nat Rev Endocrinol, Available from. [CrossRef]
- 260. Choe SS, Huh JY, Hwang IJ, Kim JI, Kim JB. Adipose tissue remodeling: Its role in energy metabolism and metabolic disorders. Front Endocrinol.
- 261. Pawłowski B, Żelaźniewicz A. The evolution of perennially enlarged breasts in women: a critical review and a novel hypothesis. Biol Rev.
- 262. Tan CY, Vidal-Puig A. Adipose tissue expandability: The metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans.
- 263. Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep.
- 264. Echiburú B, Pérez-Bravo F, Galgani JE, Sandoval D, Saldías C, Crisosto N, et al. Enlarged adipocytes in subcutaneous adipose tissue associated to hyperandrogenism and visceral adipose tissue volume in women with polycystic ovary syndrome. Steroids, Available from, 20 November. [CrossRef]
- 265. Arpaci D, Gurkan Tocoglu A, Yilmaz S, Ergenc H, Tamer A, Keser N, et al. The relationship between epicardial fat tissue thickness and visceral adipose tissue in lean patients with polycystic ovary syndrome. J Ovarian Res, Available from. [CrossRef]
- 266. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism, Available from. [CrossRef]
- 267. Kałużna M, Czlapka-Matyasik M, Bykowska-Derda A, Moczko J, Ruchala M, Ziemnicka K. Indirect predictors of visceral adipose tissue in women with polycystic ovary syndrome: A comparison of methods. Nutrients.
- 268. Jones GW, Hill DG, Jones SA. Understanding immune cells in tertiary lymphoid organ development: It is all starting to come together. Front Immunol.
- 269. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol.
- 270. Parker J, O’Brien C, Gersh FL. Developmental origins and transgenerational inheritance of polycystic ovary syndrome. Aust New Zeal J Obstet Gynaecol.
- 271. Davenport ER, Sanders JG, Song SJ, Amato KR, Clark AG, Knight R. The human microbiome in evolution. BMC Biol.
- 272. Rizk MG, Thackray VG. Intersection of Polycystic Ovary Syndrome and the Gut Microbiome. J Endocr Soc, /: 2021;5(2):bvaa177. Available from: https, 2021.
- 273. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ.
- 274. Martinez JE, Kahana DD, Ghuman S, Wilson HP, Wilson J, Kim SCJ, et al. Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome. Front Endocrinol.
- 275. Degruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis.
- 276. Shahi SK, Ghimire S, Lehman P, Mangalam AK. Obesity induced gut dysbiosis contributes to disease severity in an animal model of multiple sclerosis. Front Immunol.
- 277. Moya A, Ferrer M. Functional Redundancy-Induced Stability of Gut Microbiota Subjected to Disturbance. Trends Microbiol, Available from. [CrossRef]
- 278. Zhao X, Jiang Y, Xi H, Chen L, Feng X. Exploration of the Relationship between Gut Microbiota and Polycystic Ovary Syndrome (PCOS): A Review. Geburtshilfe Frauenheilkd.
- 279. Yilmaz B, Terekeci H, Sandal S, Kelestimur F. Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention. Rev Endocr Metab Disord.
- 280. Fabozzi G, Rebuzzini P, Cimadomo D, Allori M, Franzago M, Stuppia L, et al. Endocrine-Disrupting Chemicals, Gut Microbiota, and Human (In) Fertility — It Is Time to Consider the Triad. Cells.
- 281. Bellingham M, Sharpe R. Chemical Exposures During Pregnancy: Dealing with Potential, but Unproven, Risks to Child Health. R Coll Obstet Gynaecol, /: Available from: http.
- 282. Di Renzo GC, Conry JA, Blake J, Defrancesco MS, Denicola N, Martin JN, et al. International Federation of Gynecology and Obstetrics opinion on reproductive health impacts of exposure to toxic environmental chemicals. Int J Gynecol Obstet.
- 283. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. EDC-2: The Endocrine Society’s Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev.
- 284. Liu Z, Lu Y, Zhong K, Wang C, Xu X. The associations between endocrine disrupting chemicals and markers of inflammation and immune responses: A systematic review and meta-analysis. Ecotoxicol Environ Saf.
- 285. Alonso-Magdalena P, Morimoto S, Ripoll C, Fuentes E, Nadal A. The estrogenic effect of bisphenol a disrupts pancreatic β-cell function in vivo and induces insulin resistance. Environ Health Perspect.
- 286. Wang Y, Zhu Q, Dang X, He Y, Li X, Sun Y. Local effect of bisphenol A on the estradiol synthesis of ovarian granulosa cells from PCOS. Gynecol Endocrinol.
- 287. Sun Y, Gao S, Ye C, Zhao W. Gut microbiota dysbiosis in polycystic ovary syndrome : Mechanisms of progression and clinical applications. Frontiers in Cellular and Infection Microbiology, 3389.
- 288. Ananthasubramanian P, Ananth S, Kumaraguru S, Barathi S, Santosh W, Vasantharekha R. Associated Effects of Endocrine Disrupting Chemicals (EDCs) on Neuroendocrine Axes and Neurotransmitter Profile in Polycystic Ovarian Syndrome Condition. Proc Zool Soc, Available from. [CrossRef]
- 289. Gupta R, Kumar P, Fahmi N, Garg B, Dutta S, Sachar S, et al. Endocrine disruption and obesity: A current review on environmental obesogens. Curr Res Green Sustain Chem, Available from, 1000. [CrossRef]
- 290. Aydemir D, Ulusu NN. The possible role of the endocrine disrupting chemicals on the premature and early menopause associated with the altered oxidative stress metabolism. Front Endocrinol.
- 291. Ravichandran G, Lakshmanan DK, Raju K, Elangovan A, Nambirajan G, Devanesan AA, et al. Food advanced glycation end products as potential endocrine disruptors: An emerging threat to contemporary and future generation. Environ Int, Available from, 20 December. [CrossRef]
- 292. Bansal A, Henao-Mejia J, Simmons RA. Immune system: An emerging player in mediating effects of endocrine disruptors on metabolic health. Endocrinology.
- 293. Tudurí E, Marroqui L, Dos Santos RS, Quesada I, Fuentes E, Alonso-Magdalena P. Timing of exposure and Bisphenol-A: Implications for diabetes development. Front Endocrinol.
- Resnik, DB. The precautionary principle and medical decision making. J Med Philos.
- 295. Schug TT, Johnson AF, Birnbaum LS, Colborn T, Guillette LJ, Crews DP, et al. Minireview: Endocrine disruptors: Past lessons and future directions. Mol Endocrinol.
- 296. More S, Bampidis V, Benford D, Bragard C, Halldorsson T, Hernández-Jerez A, et al. Guidance on risk assessment of nanomaterials to be applied in the food and feed chain: human and animal health. EFSA J.
- 297. Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril.
- 298. Jala A, Varghese B, Kaur G, Rajendiran K, Dutta R, Adela R, et al. Implications of endocrine-disrupting chemicals on polycystic ovarian syndrome: A comprehensive review. Environ Sci Pollut Res, Available from, 5848. [CrossRef]
- 299. Jozkowiak M, Piotrowska-Kempisty H, Kobylarek D, Gorska N, Mozdziak P, Kempisty B, et al. Endocrine Disrupting Chemicals in Polycystic Ovary Syndrome: The Relevant Role of the Theca and Granulosa Cells in the Pathogenesis of the Ovarian Dysfunction. Cells.
- Parker, J. A new hypothesis for the mechanism of glyphosate induced intestinal permeability in the pathogenesis of polycystic ovary syndrome. J Australas Coll Nutr Environ Med.
- 301. Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Prakash A, et al. Environmental Endocrine-Disrupting Chemical Exposure: Role in Non-Communicable Diseases. Front Public Heal.
- 302. Mitro SD, Johnson T, Zota AR. Cumulative Chemical Exposures During Pregnancy and Early Development. Curr Environ Heal reports.
- 303. Starling AP, Adgate JL, Hamman RF, Kechris K, Calafat AM, Ye X, et al. Perfluoroalkyl substances during pregnancy and offspring weight and adiposity at birth: Examining mediation by maternal fasting glucose in the healthy start study. Environ Health Perspect.
- Rosenfeld, CS. Transcriptomics and Other Omics Approaches to Investigate Effects of Xenobiotics on the Placenta. Front Cell Dev Biol.
- 305. Hewlett M, Chow E, Aschengrau A, Mahalingaiah S. Prenatal Exposure to Endocrine Disruptors: A Developmental Etiology for Polycystic Ovary Syndrome. Reprod Sci.
- 306. Corbett GA, Lee S, Woodruff TJ, Hanson M, Hod M, Charlesworth AM, et al. Nutritional interventions to ameliorate the effect of endocrine disruptors on human reproductive health: A semi-structured review from FIGO. Int J Gynecol Obstet.
- 307. Piazza MJ, Urbanetz AA. Environmental toxins and the impact of other endocrine disrupting chemicals in women’s reproductive health. J Bras Reprod Assist.
- 308. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell.
- 309. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell.



Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).